AngioDynamics预计2026财年调整每股收益$（0.35）-$（0.25）vs $（0.23）Est;预计销售额为3.05亿美元-3.1亿美元vs 304.858美元Est

2025-07-15 18:34

Fiscal Year 2026 Financial Guidance

Guidance Metric	Current Guidance (As of July 15, 2025)	Tariff Guidance Impact
Net Sales	$305 - $310 million	Limited Impact
Med Tech Net Sales Growth	12% - 15%	Limited Impact
Med Device Net Sales Growth	Flat	Limited Impact
Gross Margin	53.5% - 55.5%	Absent Tariffs: 55.0% - 56.0%
Pro Forma Adjusted EBITDA	$3.0 - $8.0 million	Absent Tariffs: $7.5M - $10.5M
Adjusted EPS	($0.35) - ($0.25)	Absent Tariffs: ($0.30) – ($0.25)
Free Cash Flow	Positive for Full Year FY2026	Absent Tariffs: Up to +$5M

Tariff Related Guidance Assumptions

For the full fiscal year 2026, the company expects a $4.0 - $6.0 million impact from tariffs. For gross margin, pro forma adjusted EBITDA, and adjusted EPS, the low end of the respective ranges assumes the highest level of tariff impact, with the high end of the respective ranges assuming the lowest level of tariff impact.

AngioDynamics预计2026财年调整每股收益$（0.35）-$（0.25）vs $（0.23）Est;预计销售额为3.05亿美元-3.1亿美元vs 304.858美元Est

推荐文章

港股周报 | 中国大模型“春节档”打响！智谱周涨超138%；巨亏超230亿！美团周内重挫超10%

一周财经日历 | 港美股迎“春节+总统日”双假期！万亿零售巨头沃尔玛将发财报

一周IPO | 赚钱效应持续火热！年内24只上市新股“0”破发；“图模融合第一股”海致科技首日飙涨逾242%

从软件到房地产，美国多板块陷入AI恐慌抛售潮

Meta计划为智能眼镜添加人脸识别技术

危机四伏，市场却似乎毫不在意

美股机会日报 | 降息预期升温！美国1月CPI年率创去年5月来新低；净利、指引双超预期！应用材料盘前涨超10%

财报前瞻 | 英伟达Q4财报放榜在即！高盛、瑞银预计将大超预期，两大关键催化将带来意外惊喜？